Colirio de suero autólogo

Silvia Amado; Santiago Pérez; Wilson Franca; Karina Vidiñapin; Diego Lasserre

doi:10.35954/SM2016.35.1.5

Authors

Silvia Amado Médico Oflalmólogo, Jefa del Servicio de Oftalmología de Médica Uruguaya.
Santiago Pérez Médico Oftalmólogo del Servicio de Oftalmología de Médica Uruguaya.
Wilson Franca Médico Hemoterapeuta, Jefe del Servicio de Hemoterapia de Médica Uruguaya, Médico Hemot. G° III de Casmu, Médico Hemot. Hospital Maciel y miembro del Equipo de TMO de Hospital Maciel.
Karina Vidiñapin Tecnóloga en Hemoterapia, Especialista en Gestión de la Calidad en Servicios de Salud, Unidad de Control de Calidad de Hemoterapia Médica Uruguaya, Tecnóloga en Hemoterapia en Servicio Nacional de Sangre.
Diego Lasserre Tecnólogo en Hemoterapia, Unidad de Control de Calidad de Hemoterapia Médica Uruguaya, Tecnólogo en Hemot. Hospital Maciel

DOI:

https://doi.org/10.35954/SM2016.35.1.5

Keywords:

Ophthalmology, Corneal Transplantation, Dry Eye Syndromes, Eye Abnormalities

Abstract

The use of Autologous Serum Eye Drops in Ophthalmology has been implemented due to the need to find a tear substitute that, in addition to humidifying, provides other fundamental factors in the treatment of different ocular surface disorders, such as Dry Eye Syndrome or Dry Keratoconjunctivitis and Persistent Epithelial Defects. Autologous Serum Eye Drops have characteristics very similar to those of tears in terms of PH and osmolarity, providing nutritional and growth factors necessary to maintain cell viability in epithelial repair processes. It also contains bactericidal substances that reduce the risk of contamination and infection. For its preparation under aseptic conditions, adequate equipment is required: laminar flow chamber, sterile material and properly trained personnel. Serum extracted from the patient's own blood is used, that is why it is called Autologous, and there is no risk of transmission of infectious-contagious. diseases.ranslated with www.DeepL.com/Translator (free version)

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

(1) Kanski J. Oftalmología Clínica. 3a. ed. Barcelona : Doyma, 1996, 73-6.

(2) López-García J, García Lozano I, Martínez-Garchitorena J. Use of autologous serum in ophthalmic practice. Arch Soc Esp Ophthalmol 2007; 82(1): 9-20.

(3) Ralph R, Doane M, Dohlman C. Clinical experience with a mobile ocular perfusion pump. Arch Ophthalmol 1975; 93(10):1039-43.

(4) Fox R, Chan R, Michelson J, Belmont J, Michelson P. Beneficial effect of artificial tears, made with autologous serum in patiens with Keratoconjunctivitis sicca. Arthritis Rheum 1984; 27(4):459-61.

(5) Tsubota K, Satake Y, Ohyama M, Toda I, Takano Y, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. Am J Ophthalmol 1996; 122(1):38-52.

(6) Tsubota K, Goto E, Shimura S, Shimazaki J. Treatment of persistent epitelial defect by autologous serum application. Ophthalmology 1999; 106(10):1984-9.

(7) Pflugfelder S, Geerling G, Kinoshita S, Lemp M, McCulley J, Nelson D, et al. Manejo y tratamiento de la enfermedad de ojo seco: informe del Subcomité para Manejo y Tratamiento del Ojo Seco. Ocul Surf 2007; 5(2):168-83.

(8) Mathers W. Why the eye becomes dry: A cornea and lacrimal gland feedback model. CLAO J 2000; 26(3):159-65.

(9) Krause F, Tseng S. Serum differentially modulates the clonal growth and differentiation of cultured limbal and corneal epithelium. Invest Ophthalmol Vis Sci 993; 34(10):2976-89.

(10) Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol 1999; 83(4):390-395.

(11) Van Setten G, Tervo T, Tervo K, Tarkkanen A. Epidermal growth factor (EGF) in ocular fluids: presence, origin and therapeutical considerations. Acta Ophthalmol Suppl 1992; 202: 54-9.

(12) Collins M, Perkins G, Rodríguez-Tarduchy G, Nieto M, López-Rivas A. Growth factors as survival factors: Regulation of apoptosis. Bioessays 1994; 16(2):133-38.

(13) Ohashi Y, Motokura M, Kinoshita Y, Mano T, Watanabe H, Kinoshita S, et al. Presence of epidermal growth factor in human tears. Invest Ophthalmol Vis Sci 1989; 30(8):1879-82.

(14) Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder S. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res 1996; 15(6):605-14.

(15) Fredj-Reygrobellet D, Plouet J, Delayre T, Baudouin C, Bourret F, Lapalus P. Effects of aFGF and bFGF on wound healing in rabbit corneas. Curr Eye Res 1987; 6(10):1205-9.

(16) Yoshino K, Garg R, Monroy D, Ji Z, Pflugfelder S. Production and secretion of transforming growth factor beta (TGF-beta) by the human lacrimal gland. Curr Eye Res 1996; 15(6):615-24.

(17) Wilson S, Lloyd S, Kennedy R. Basic fibroblast growth factor (FGFb) and epidermal growth factor (EGF) receptor messenger RNA production in human lacrimal gland. Invest Ophthalmol Vis Sci 1991; 32(10):2816-20.

(18) Shimmura S, Ueno R, Matsumoto Y, Goto E, Higuchi A, Shimazaki J, et al. Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol 2003; 87(10):1279-83.

(19) Poon A, Geerling G, Dart J, Fraenkel G, Daniels J. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85(10):1188-97.

(20) Nishida T, Ohashi Y, Awata T, Manabe R. Fibronectin. A new therapy for corneal trophic ulcer. Arch Ophthalmol 1983; 101(7):1046-48.

(21) Phan T, Foster C, Shaw C, Zagachin L, Colvin R. Topical fibronectin in an alkali burn model of corneal ulceration in rabbits. Arch Ophthalmol 1991; 109(3):414-19.

(22) Nishida T, Nakamura M, Ofuji K, Reid T, Mannis M, Murphy C. Synergistic effects of substance P with insulinlike growth factor-1 on epithelial migration of the cornea. J Cell Physiol 1996; 169(1):159-66.

(23) Donate J, Benítez del Castillo J, Fernández C, García Sánchez J. Validation of a questionnaire for the diagnosis of dry eye. Arch Soc Esp Oftalmol 2002; 77(9):493-500.